Financial Assistance Options

No matter what type of health insurance you have, you may have options to help you afford your medicine. Options may be available to you even if you have no health insurance at all.

Get Started with Financial Assistance Tool

Use our financial assistance tool to see which programs may be right for you.

Get started

If you would rather talk through some potential options, call us at 888-249-4918 (6AM-5PM PST, Monday through Friday).


Help With Co-pay Costs

These groups may help you pay for TECENTRIQ HYBREZA if you have insurance but still need help with costs:

Help With Costs for TECENTRIQ HYBREZA

Co-pay Card Assistance

With the Genentech Oncology Co-pay Assistance Program, eligible patients with commercial insurance may pay as little as $0 per treatment for TECENTRIQ HYBREZA. The program may be able to assist with co-pay or co-insurance up to $25,000 per calendar year.

You may be eligible if you:

  • Have been prescribed TECENTRIQ HYBREZA for an FDA-approved indication
  • Are 18 years of age or older, or have a caregiver or legally authorized person to manage the patient's co-pay assistance
  • Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance exchanges
  • Reside and receive treatment in the U.S. or U.S. Territories
  • Are not receiving assistance through the Genentech Patient Foundation or any other charitable organization for the same expenses covered by the program
  • Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (e.g., Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE)

The Co-pay Program (“Program”) is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. The Program is not available to patients whose prescriptions are reimbursed under any federal, state, or government-funded insurance programs (included but not limited to Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs Programs) or where prohibited by law or by the patient's health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state or government-funded healthcare programs, the patient will no longer be eligible for the Program.

Under the Program, the patient may be required to pay a co-pay. The final amount owed by a patient may be as little as $0 for the Genentech medicine (see Program specific details available at the Program website). The total patient out-of-pocket cost is dependent on the patient’s health insurance plan. The Program assists with the cost of the Genentech medicine only. It does not assist with the cost of other medicines, procedures or office visit fees. After reaching the maximum annual Program benefit amount, the patient will be responsible for all remaining out-of-pocket expenses. The Program benefit amount cannot exceed the patient’s out-of-pocket expenses for the Genentech medicine.

All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. The Program is only valid in the United States and U.S. Territories, is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. No party may seek reimbursement for all or any part of the benefit received through the Program. The value of the Program is intended exclusively for the benefit of the patient. The funds made available through the Program may only be used to reduce the out-of-pocket costs for the patient enrolled in the Program. The Program is not intended for the benefit of third parties, including without limitation third party payers, pharmacy benefit managers, or their agents. If Genentech determines that a third party has implemented a program that adjusts patient cost-sharing obligations based on the availability of support under the Program and/or excludes the assistance provided under the Program from counting towards the patient’s deductible or out-of-pocket cost limitations, Genentech may impose a per fill cap on the cost-sharing assistance available under the Program. Submission of true and accurate information is a requirement for eligibility and Genentech reserves the right to disqualify patients who do not comply with Genentech Program Terms and Conditions. Genentech reserves the right to rescind, revoke or amend the Program without notice at any time.

Additional terms and conditions apply. Please visit the Co-pay Program website for the full list of Terms and Conditions.

View full TERMS AND CONDITIONS

Independent Co-pay Assistance

An independent co-pay assistance foundation is a charitable organization providing financial assistance to patients with specific disease states, regardless of treatment. Patients who are commercially or publicly insured, including those covered by Medicare and Medicaid, can contact the foundations directly to request assistance. Eligibility requirements, all aspects of the application process, turnaround times and the type or amount of assistance available (if any) can vary by foundation. 

These foundations may be able to help. Please check their websites for up-to-date information.

These organizations are independent of Genentech and may require you to provide personal or financial information directly to the organization to enroll in their respective programs. Genentech cannot share any information you have provided to us.

Independent co-pay assistance foundations have their own rules for eligibility. We have no involvement or influence in independent foundation decision-making or eligibility criteria and do not know if a foundation will be able to help you. We can only refer you to a foundation that supports your disease state. This information is provided as a resource for you. We do not endorse or show preference for any particular foundation. The foundations in this list may not be the only ones that might be able to help you.


Genentech Patient Foundation

If you don’t have health insurance coverage or have financial concerns and meet eligibility criteria, this program may help:

Genentech Patient Foundation

The Genentech Patient Foundation gives free TECENTRIQ HYBREZA to people who have been prescribed this medicine and don’t have insurance or who have financial concerns and meet certain eligibility criteria.

You may be eligible if your insurance coverage and income match one of these situations:

  • Uninsured patients with incomes under $150,000
  • Insured patients without coverage for TECENTRIQ HYBREZA with incomes under $150,000
  • Insured patients with coverage for a Genentech medicine:
    • With an out-of-pocket maximum set by their health insurance plan that exceeds 7.5% of their household income
    • With household size and income within certain guidelines

For any of these situations, add $25,000 for each extra person in households larger than 4 people.

We encourage insured patients to try other financial assistance options before applying for help from the Genentech Patient Foundation, if possible.

Enrollment Process for the Genentech Patient Foundation

To get started:

  1. Complete the Patient Consent Form, which is available in English and Spanish, below:
  2. Once you have completed the Patient Consent Form, please let your doctor’s office know that you are applying for assistance with the Genentech Patient Foundation. Your doctor will have to complete another form called the Prescriber Foundation Form. Both forms are required. We must have both the Patient Consent Form and the Prescriber Foundation Form before we can help you.

What to expect next:

  • The request will be processed within five business days upon receipt of both required forms.
  • You and your provider will be contacted to discuss any next steps.

Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.

If you have any questions about the criteria, please contact a Foundation Specialist at 888-941-3331 (Mon.–Fri., 6AM–5PM PST).


Get Started with Financial Assistance Tool

Use our financial assistance tool to see which programs may be right for you.

Get started

  • Commercial insurance: An insurance plan you get from a private health insurance company. This can be insurance from your job, from a plan you bought yourself or from a Health Insurance Marketplace. Medicare and Medicaid are not considered commercial insurance.

  • Public insurance: A health insurance plan you get from the federal or state government. This includes Medicare, Medicaid, TRICARE and DoD/VA insurance.

  • We are open from 6AM-5PM PST, Mon. through Fri., except for the following holidays:

    • New Year’s Day
    • Martin Luther King, Jr. Day
    • Memorial Day
    • Independence Day
    • Labor Day
    • Thanksgiving Holiday (Thursday and Friday)
    • Christmas Day
  • For example, a household size of 1 with income of less than $75,000 may meet the criteria for assistance. Add $25,000 for each additional person in the household. There is no maximum number of people you may add.

Important Safety Information & Indications

Indications

What are TECENTRIQ and TECENTRIQ HYBREZA?

TECENTRIQ (atezolizumab) and TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) are prescription medicines used to treat:

Adults with a type of lung cancer called non-small cell lung cancer (NSCLC).

  • TECENTRIQ or TECENTRIQ HYBREZA may be used alone as a treatment for your lung cancer:
    • to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery and you have received platinum-based chemotherapy, and
    • you have stage 2 to stage 3A NSCLC (talk to your healthcare provider about what these stages mean), and
    • your cancer tests positive for “PD-L1”.
  • TECENTRIQ or TECENTRIQ HYBREZA may be used alone as your first treatment when your lung cancer:
    • has spread or grown, and
    • your cancer tests positive for “high PD-L1”, and
    • your tumor does not have an abnormal “EGFR” or “ALK” gene.
  • TECENTRIQ HYBREZA may be used with the medicines bevacizumab, paclitaxel, and carboplatin as your first treatment when your lung cancer:
    • has spread or grown, and
    • your cancer tests positive for “high PD-L1”, and
    • your tumor does not have an abnormal “EGFR” or “ALK” gene.
  • TECENTRIQ or TECENTRIQ HYBREZA may be used with the medicines bevacizumab, paclitaxel, and carboplatin as your first treatment when your lung cancer:
    • has spread or grown, and
    • is a type called “non-squamous NSCLC”, and
    • your tumor does not have an abnormal “EGFR” or “ALK” gene.
  • TECENTRIQ or TECENTRIQ HYBREZA may be used with the medicines paclitaxel protein-bound and carboplatin as your first treatment when your lung cancer:
    • has spread or grown, and
    • is a type called “non-squamous NSCLC”, and
    • your tumor does not have an abnormal “EGFR” or “ALK” gene.
  • TECENTRIQ or TECENTRIQ HYBREZA may be used alone when your lung cancer:
    • has spread or grown, and
    • you have tried chemotherapy that contains platinum, and it did not work or is no longer working.
    • If your tumor has an abnormal “EGFR” or “ALK” gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

Adults with a type of lung cancer called “extensive stage small cell lung cancer (SCLC)”, which is SCLC that has spread or grown

  • TECENTRIQ or TECENTRIQ HYBREZA may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment
  • TECENTRIQ or TECENTRIQ HYBREZA may be used with the medicine lurbinectedin as maintenance treatment when your lung cancer:
    • has not progressed after first treatment with TECENTRIQ or TECENTRIQ HYBREZA and the chemotherapy medicines carboplatin and etoposide.

Adults with a type of liver cancer called hepatocellular carcinoma (HCC). TECENTRIQ or TECENTRIQ HYBREZA may be used with the medicine bevacizumab when your liver cancer:

  • has spread or cannot be removed by surgery, and
  • you have not received other medicines by mouth or injection through your vein (IV) to treat your cancer.

Adults with a type of bladder cancer called muscle invasive bladder cancer (MIBC) that has spread into the muscle layer of the bladder but not to other parts of the body. TECENTRIQ or TECENTRIQ HYBREZA may be used alone as a treatment for your bladder cancer:

  • to help prevent your bladder cancer from coming back after your bladder has been removed by surgery, and
  • small pieces of DNA from the tumor (called circulating tumor DNA [ctDNA]) were found in your blood, showing that cancer cells remain in the body (molecular residual disease). Your healthcare provider will perform a test to make sure that TECENTRIQ or TECENTRIQ HYBREZA is right for you.

It is not known if TECENTRIQ HYBREZA is safe and effective when used:

  • in children for the treatment of NSCLC, SCLC, HCC or MIBC.

It is not known if TECENTRIQ is safe and effective when used:

  • in children for the treatment of NSCLC, SCLC, HCC or MIBC.
TECENTRIQ and TECENTRIQ HYBREZA Important Safety Information

Who should not receive TECENTRIQ HYBREZA?
Do not receive TECENTRIQ HYBREZA if you
are allergic to hyaluronidase or any of the ingredients in TECENTRIQ HYBREZA

What is the most important information about TECENTRIQ and TECENTRIQ HYBREZA?
TECENTRIQ and TECENTRIQ HYBREZA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

Lung problems

  • cough
  • shortness of breath
  • chest pain

Intestinal problems

  • diarrhea (loose stools) or more frequent bowel movements than usual
  • stools that are black, tarry, sticky, or have blood or mucus
  • severe stomach-area (abdomen) pain or tenderness

Liver problems

  • yellowing of your skin or the whites of your eyes
  • severe nausea or vomiting
  • pain on the right side of your stomach area (abdomen)
  • dark urine (tea colored)
  • bleeding or bruising more easily than normal

Hormone gland problems

  • headaches that will not go away or unusual headaches
  • eye sensitivity to light
  • eye problems
  • rapid heartbeat
  • increased sweating
  • extreme tiredness
  • weight gain or weight loss
  • feeling more hungry or thirsty than usual
  • urinating more often than usual
  • hair loss
  • feeling cold
  • constipation
  • your voice gets deeper
  • dizziness or fainting
  • changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

Kidney problems

  • decrease in your amount of urine
  • blood in your urine
  • swelling of your ankles
  • loss of appetite

Skin problems

  • rash
  • itching
  • skin blistering or peeling
  • painful sores or ulcers in your mouth or your nose, throat, or genital area
  • fever or flu-like symptoms
  • swollen lymph nodes

Problems can also happen in other organs.
These are not all of the signs and symptoms of immune system problems that can happen with TECENTRIQ or TECENTRIQ HYBREZA. Call or see your healthcare provider right away for any new or worsening signs or symptoms, including:

  • Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles
  • Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
  • Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
  • Persistent or severe muscle pain or weakness, muscle cramps
  • Low red blood cells, bruising

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:

  • chills or shaking
  • itching or rash
  • flushing
  • shortness of breath or wheezing
  • dizziness
  • feeling like passing out
  • fever
  • back or neck pain

Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had.

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with TECENTRIQ or TECENTRIQ HYBREZA. Your healthcare provider will monitor you for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with TECENTRIQ or TECENTRIQ HYBREZA. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with TECENTRIQ or TECENTRIQ HYBREZA if you have severe side effects.

Before you receive TECENTRIQ or TECENTRIQ HYBREZA, tell your healthcare provider about all of your medical conditions, including if you:

  • have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
  • have received an organ or tissue transplant, including corneal transplant
  • have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
  • have received radiation treatment to your chest area
  • have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
  • are pregnant or plan to become pregnant. TECENTRIQ and TECENTRIQ HYBREZA can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TECENTRIQ or TECENTRIQ HYBREZA. Females who are able to become pregnant:
    • Your healthcare provider should do a pregnancy test before you start treatment with TECENTRIQ or TECENTRIQ HYBREZA.
    • You should use an effective method of birth control during your treatment and for at least 5 months after the last dose of TECENTRIQ or TECENTRIQ HYBREZA.
  • are breastfeeding or plan to breastfeed. It is not known if TECENTRIQ or TECENTRIQ HYBREZA passes into your breast milk. Do not breastfeed during treatment and for at least 5 months after the last dose of TECENTRIQ or TECENTRIQ HYBREZA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of TECENTRIQ when used alone include:

  • feeling tired or weak
  • decreased appetite
  • nausea
  • cough
  • shortness of breath

The most common side effects of TECENTRIQ HYBREZA when used alone include:

  • feeling tired or weak
  • muscle or bone pain
  • cough
  • shortness of breath
  • decreased appetite

The most common side effects of TECENTRIQ and TECENTRIQ HYBREZA when used in lung cancer with other anti-cancer medicines include:

  • feeling tired or weak
  • nausea
  • hair loss
  • constipation
  • diarrhea
  • decreased appetite

The most common side effects of TECENTRIQ and TECENTRIQ HYBREZA when used in hepatocellular carcinoma (HCC) with bevacizumab include:

  • high blood pressure
  • feeling tired or weak
  • too much protein in the urine

The most common side effect of TECENTRIQ and TECENTRIQ HYBREZA when used alone in MIBC is:

  • urinary tract infection

TECENTRIQ and TECENTRIQ HYBREZA may cause fertility problems in females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of TECENTRIQ and TECENTRIQ HYBREZA. Ask your healthcare provider or pharmacist for more information about the benefits and side effects of TECENTRIQ and TECENTRIQ HYBREZA.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for TECENTRIQ and TECENTRIQ HYBREZA and the Medication Guides for TECENTRIQ and TECENTRIQ HYBREZA for additional Important Safety Information.

+